FOXP3 and neoplasm: CD4+ TILs exhibited heterogeneous expression of both T-bet and FoxP3 in established tumours (D14 & D21), while CD4+ TILs in early-stage tumours (D7) were mainly FoxP3-T-bet- (75% of total CD4+ TILs; Figure 7A).